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HIGHLIGHTS 
 GnRH and ZP-based vaccines induced reversible suppression of ovarian cyclic activity 
in mares 
 Domesticated mares provided an appropriate clinical and laboratory model for 
observations of the effects of immunocontraceptive vaccines for wildlife and feral 
horses 
 The incorporation of non-Freund’s adjuvants in recombinant and native zona 
pellucida vaccine formulations showed promising immunological and safety profile 
responses in treated mares 
 
ABSTRACT 
A sequence of studies is reviewed that reported the domestic horse (Equus caballus) mare 
as an appropriate and accessible research platform for recording clinical and laboratory data 
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post-immunisation with anti- GnRH and -zona pellucida (ZP) immunocontraceptive vaccines. 
Experience with a native porcine ZP (pZP) vaccine in African elephant (Loxodonta africana) 
cows highlighted needs for improving vaccine formulations and more clearly defining 
associated ovarian effects and safety profiles. Initially, the efficacy, reversibility and safety of 
the GnRH vaccine Improvac® in mares was demonstrated using reproductive tract 
ultrasonography and concurrently measuring serum antibody titres and progesterone 
concentrations. Results informed the study design and minimally invasive monitoring of 
post-treatment ovarian steroid responses of this vaccine in free-ranging African elephant 
cows. A subsequent sequence of studies reported reversible contraceptive and 
immunological efficacy in pony mares immunised with pZP formulated with Freund’s 
adjuvants. By comparison, mares treated with a recombinant ZP3 and ZP4 (reZP) vaccine 
showed disappointing responses. Unexpectedly, most pZP-treated mares showed ovarian 
inactivity. In attempting to understand this response, results showed the involvement of 
cytotoxic (CD8+) T-cells negatively correlated to serum ovarian steroid and anti-Müllerian 
hormone (AMH) levels.  Of concern was the prevalence of injection-site lesions ascribable to 
Freund’s adjuvants. Following this, mares treated with both pZP and a novel reZP vaccine 
formulated with non-Freund’s adjuvants showed comparable immunological responses and 
ovarian inactivity, notably without adverse treatment reactions. In addition, measuring AMH 
showed promise for monitoring ovarian function in anti-ZP-treated animals. 
 
Keywords. Horse; African elephant; Immunocontraception; Vaccine formulation 
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1. Introduction 
In most African countries, the African elephant (Loxodonta africana) is listed in the 
Convention on International Trade in Endangered Species (CITES) Appendix I as threatened 
with extinction. In contrast, populations in Botswana, Zimbabwe, Namibia and South Africa 
are burgeoning. The manipulation of these populations’ growth rates is of critical 
importance to the future survival of populations and habitats. Lack of resources can result in 
elephant breakouts and human-wildlife conflict issues. Additionally, an over population of 
elephants has negative effects on other species through habitat degradation (Delsink et al., 
2006; Kerley and Shrader, 2007; Valeix et al., 2008; Gandiwa et al., 2011).  
Similarly, the presence of feral horses is associated with negative environmental effects, 
including soil compaction and erosion, damage to water bodies and disruption of local 
ecosystems (Nimmo and Miller, 2007). Yet, like the elephant, the horse attracts significant 
public empathy, with many populations now protected by law (Garrott and Oli, 2013).  
 Immunocontraceptive vaccines represent a promising means of population control for 
wildlife and feral species. Immunocontraceptives induce infertility via antibody production 
subsequent to stimulation by one or other antigenic component critical to reproductive 
pathways (Fayrer-Hosken, 2008). Vaccines have been successfully applied in many domestic 
and wildlife species as they offer a potentially cost-effective, minimally invasive and non-
lethal alternative to traditional methods of population control such as culling and surgical 
sterilisation (Kirkpatrick et al., 2011).  
 The current focus of immunocontraceptive research and its management applications is 
with the anti-porcine zona pellucida (pZP) and -GnRH vaccines. The first reported application 
of immunocontraceptive vaccines in horses (Equus caballus) described the testing of a GnRH 
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vaccine (Garza et al., 1986) followed shortly thereafter by an investigation into pZP 
vaccination in this species (Liu et al., 1989).  Subsequent reports most notably described 
administration of pZP vaccines in populations of feral horses in North America (Kirkpatrick et 
al., 1995; Turner et al., 2002; Turner et al., 2007; Killian et al., 2008; Bechert et al., 2013). 
The horse was reported as both a laboratory (Liu et al., 1989; Willis et al., 1994) and 
ecological model (Turner et al., 2002) within this body of research.  
 1.1 Scope of review  
Researchers from the Veterinary Population Management Laboratory of the University of 
Pretoria reported on a series of studies from 2008-2019 (Botha et al., 2008; Benavides 
Valades et al., 2012; Schulman et al., 2013; Joonè et al., 2017a; Joonè et al., 2017b; 
Bertschinger et al., 2018; Joonè et al., 2018; Nolan et al., 2018; Joonè et al., 2019; Nolan et 
al., 2019).  These studies investigated the immunological and contraceptive efficacy, safety 
profiles and ovarian effects of administration of both a commercially available GnRH vaccine 
and various zona pellucida (ZP)-based vaccine formulations primarily in pony and horse 
mares. Our laboratory hypothesized that immunocontraceptive research in the domestic 
mare, while informing practical immunocontraceptive application to feral horses, would also 
be a promising model for the African elephant. Notably, domestic mares provided a more 
accessible research platform for recording clinical and laboratory data than would be 
possible in the African elephant cow and indeed in feral horse populations. Both mares and 
elephants are considered to be monovular and polyoestrous (Perry, 1953; Asa et al., 1979), 
although the oestrous cycle and gestation length of the elephant cow are markedly more 
protracted than in the mare (Ahlers et al., 2012). Both species are long-lived with complex 
social structures. The elephant social structure is matriarchal, with one cow presiding over a 
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herd of females and young (Gobush et al., 2009). In comparison, the free-roaming horse 
exists in a harem with a dominant stallion leading a herd of females and young, however the 
presence of dominant mares complements this system (Nuñez, 2009).  Given the paucity of 
information related to reproductive physiology in the African elephant, further research to 
validate the mare as a model for this species is warranted. Interestingly, the mare is well 
established as an appropriate comparative animal model of reproductive dynamics in 
women (Ginther et al., 2004; Carnevale, 2008; Ginther, 2012). Similarly, the African elephant 
holds potential as a model for reproductive function in women, given the similarity in 
reproductive lifespan between the two species (Stansfield et al., 2011).  
This review focuses on research objectives that investigated:  
 Immunological, ovarian and contraceptive effects, reversibility and safety profile of a 
GnRH vaccine, Improvac® (Zoetis Animal Health, South Africa) (Botha et al., 2008; 
Schulman et al., 2013) and a native porcine zona pellucida (pZP) vaccine formulation 
derived from sow ovaries harvested post-slaughter (Joonè et al., 2017a; Nolan et al., 
2018; Joonè et al., 2019; Nolan et al., 2019); 
 Development and validation of minimally-invasive methods for measuring post-
vaccination ovarian cyclical responses (Botha et al., 2008; Schulman et al., 2013; 
Joonè et al., 2018; Nolan et al., 2018);  
 Application of this method to measure the response to Improvac® in free-ranging 
African elephant cows (Benavides Valades et al., 2012); 
 Describing ovarian inactivity as an associated feature of ZP-based vaccination (Joonè 
et al., 2017a; Joonè et al., 2017b; Joonè et al., 2018; Nolan et al., 2018); 
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 Immunological, ovarian and contraceptive effects associated with vaccination using 
alternative ZP antigens, specifically recombinant ZP3 and ZP4 proteins (reZP) (Joonè 
et al., 2017a; Joonè et al., 2018; Joonè et al., 2019) and  
 Alternative ZP vaccine formulations, specifically native pZP and reZP antigens 
formulated with non-Freunds adjuvants (Nolan et al., 2018; Nolan et al., 2019). 
 
2. Investigating anti-GnRH vaccination in mares and elephant cows 
 In mares, pZP vaccination was reported as an effective contraceptive method that 
neither prevented oestrous cyclicity nor suppressed its related behaviours (Kirkpatrick et al., 
2009).  In contrast, GnRH vaccines induce production of antibodies to GnRH, preventing 
GnRH binding to the pituitary gonadotrophs with subsequent suppression of luteinising 
hormone (LH) and, to a lesser extent, follicle stimulating hormone (FSH) secretion. This 
withdrawal of gonadotrophic support for cyclical ovarian follicular activity ultimately results 
in anoestrus (Stout and Colenbrander, 2004; Hennessy, 2008). Several studies using GnRH 
vaccines reported variably successful but variable suppression of ovarian activity preventing 
oestrus behaviour in adult mares (Garza et al., 1986; Tshewang et al., 1997; Dalin et al., 
2002; Stout and Colenbrander, 2004; Imboden et al., 2006). Additionally, age-associated 
effects on both ovarian response (Dalin et al., 2002; Stout and Colenbrander, 2004) and 
injection-site reactions (Stout and Colenbrander, 2004) to treatment were reported. Small 
study populations and brief monitoring periods that prevented observations of reversibility 
and the associated duration of vaccination-induced anoestrus limited these reports.  
Our group’s initial investigations assessed the potential of anti-GnRH vaccines as an 
effective, reversible and safe alternative to the well-established administration of pZP 
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vaccines in horse mares (Botha et al., 2008; Schulman et al., 2013). Following reports of the 
successful down-regulation of aggression and androgen-related behaviours via an anti-GnRH 
vaccine in African elephant bulls (De Nys et al., 2003; De Nys et al., 2010) these 
investigations additionally aimed at informing future application of these vaccines in free-
ranging African elephant cows. The response to treatment was monitored via  serial 
measurements of faecal androgen metabolite concentrations (Palme and Möstl, 1994), 
already validated in this species (Ganswindt et al., 2002).  
 Our study’s primary aims were to observe the effects of active immunisation against 
GnRH on ovarian cyclic activity, reversibility, immunological responses and safety profile in a 
large group of horse mares (n= 65) during a 720 d observation period. Mares were age-
categorised to observe age effects on treatment and a saline-treated control group was 
included. All treated mares received two gluteal intramuscular injections of 400 µg 
Improvac® (RnRF-protein conjugate, Zoetis Animal Health, South Africa) with a 35 d interval 
between treatments. Clinical data included findings from trans-rectal palpation and 
ultrasonographical examination of the internal reproductive tract, monitoring of general 
health parameters and injection sites. Laboratory data obtained by serial blood sampling 
measured serum progesterone concentration (SPC) via radioimmune assay (RIA) and anti-
GnRH antibody titres by enzyme immunoassay (EIA). By 70 d post-treatment, all treated 
mares showed clinical and SPC measurements consistent with anoestrus. By 720 d, 92.2% 
resumed cyclic ovarian activity with a mean interval of 417.8 d (range: 232-488 d).  
Significantly, an age effect on the interval to resumption, but not on antibody response, 
was observed between the youngest (< 4 y) with the longest interval, and the oldest (> 11 
y), mare categories. Injection-site reactions were mild and transient in nature. Usefully, the 
close concordance in this large group between clinical variables and SPC served to validate 
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SPC as a minimally invasive measure of ovarian cyclical activity. This would potentially 
obviate (or at least minimise) more invasive clinical interventions when studying the cyclical 
effects of planned future vaccine treatment in free-ranging mares or wildlife species 
(Schulman et al., 2013). 
Informed by the mare study and using a similar study design, Improvac® was 
administered for the first time in a group of free-ranging adult African elephant cows 
(Benavides Valades et al., 2012). This controlled study noninvasively monitored eight 
treated cows (two treatments of 600 µg Improvac® per 3 ml dart-delivered intramuscular 
dose) and four control cows over 12 months using faecal progesterone metabolite 
concentrations (FPMC) to assess the resultant cyclic ovarian activity. Vaccination failed to 
induce anoestrus in treated cows. Partially at least, this result was ascribed to an 
ineffectively low treatment dose.  Subsequent investigations reported the efficacy of 
Improvac® at 1000 µg per dose in African elephant bulls with two initial treatments five 
weeks apart and subsequent booster intervals of 5-6 months (Bertschinger and Lueders, 
2018), and ovarian suppression required more frequent administration at higher doses 
(Boedeker et al., 2012; Bertschinger and Lueders, 2018). Furthermore, the monitoring 
period proved too brief to distinguish the normal occurrence of an environmental dry 
season anoestrus from that due to the GnRH vaccine (Benavides Valades et al., 2012). 
However, the results indicated the occurrence of irregular oestrous cycles in free-ranging 
elephants similar to captive elephants and a probable relationship between ecological 
conditions and endocrine activity. 
 
3. Investigating ZP-based vaccination  
3.1 Native pZP vaccine in mares  
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Traditionally, the mechanism of action of anti-pZP vaccines was considered to be an 
antibody-based block to sperm-oocyte binding and subsequent fertilisation (Barber and 
Fayrer-Hosken, 2000). In theory, therefore, pZP should exert little influence on the ovary 
and reproductive cyclicity. This factor has been an important determinant in its selection as 
a preferred immunological method of population control in species with complex social 
structures including horses and African elephants (Fayrer-Hosken et al., 2000; Kirkpatrick et 
al., 2011). However, reported ovarian dysfunction associated with pZP vaccination in rabbits 
(Wood et al., 1981), non-human primates (Gulyas et al., 1983), dogs (Mahi-Brown et al., 
1988) and sheep (Stoops et al., 2006) supported further research defining the vaccine’s 
mechanism of action. The few reports describing ovarian effects in the mare included an 
early study reporting no affect one year after treatment (Liu et al., 1989) and conflicting 
results from studies involving repeated contraceptive treatments in feral horse populations 
(Kirkpatrick et al., 1992; Kirkpatrick et al., 1995; Powell and Monfort, 2001). More recently, a 
long-acting pZP vaccine formulation resulted in ovarian inactivity in nearly all treated mares 
(Bechert et al., 2013). 
Experience with pZP vaccination for fertility control in African elephant cows highlighted 
both the needs for improvement of both the available vaccine formulations and 
understanding of their effects on targeted animals (Fayrer-Hosken et al., 2000; Bertschinger 
et al., 2008; Ahlers et al., 2012; Bertschinger et al., 2012; Delsink et al., 2013; Bertschinger 
and Caldwell, 2016; Bertschinger et al., 2017).  The current vaccine, produced and supplied 
solely by the Veterinary Population Management Laboratory (University of Pretoria) in 
terms of current national legislation (Bertschinger et al., 2018), consists of solubilised pZP 
proteins produced from abattoir-derived pig ovaries and formulated with Freund’s modified 
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complete adjuvant (FMCA) as a primary and Freund’s incomplete adjuvant (FIA) as a booster 
dose, respectively.  
Together with an increased awareness of potentially deleterious ovarian and vaccine 
reactions reported in the mare, these considerations prompted us to identify several further 
research priorities. These included investigating immunological, ovarian, contraception and 
safety effects associated with alternative ZP antigens, specifically recombinant ZP3 and ZP4, 
and investigations into non-Freund’s adjuvants. Study designs, informed by the GnRH 
vaccine studies, again employed domestic horse mares as a research platform to obtain 
clinical and laboratory data.  
A randomly allocated group of pony mares (n=7) was treated with native pZP 
incorporating FMCA and FIA into primary and booster vaccinations respectively. Mares were 
monitored via transrectal palpation and ultrasonography of the reproductive tract and 
serum sampling for antibody titres and ovarian steroid measurements. Post-treatment, any 
cyclic mares were artificially inseminated using fresh semen at an optimal breeding time. 
One mare showed continued oestrous cyclicity characterised with apparently normal, but 
infertile, ovulations. Notably, however, the remaining six mares showed aberrant oestrous 
cyclicity, characterised by intermittent to persistent anoestrus. These results suggested that 
infertility during pZP immunocontraception was, at least, as much a result of ovarian 
inactivity as it was to an antibody-based block to sperm-oocyte binding (Joonè et al., 2017a).  
This study incorporated the novel application of measuring anti-Müllerian hormone 
(AMH) levels following pZP treatment. Mares treated with pZP showed significantly lower 
levels of AMH than control mares (Joonè et al., 2018). As AMH is expressed primarily by 
granulosa cells of  small to medium sized follicles (Claes et al., 2014), these results suggested 
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either profound inhibition of follicular development or abnormal granulosa cell function 
during effective pZP immunocontraception.  
 In attempting to understand the observed ovarian response, these studies additionally 
investigated the cell-mediated immune response to ZP-based vaccines in domestic mares. 
Previously it was hypothesized that cytotoxic (CD8+) T-cells were responsible for the ovarian 
effects of pZP vaccines in other species (Millar et al., 1989; Bradley et al., 1999; Prasad et al., 
1999; Hinds et al., 2003; Barfield et al., 2006). Interestingly, our results confirmed that both 
helper (CD4+) and cytotoxic T-cells were involved in the immune response to pZP in mares. 
Moreover, significant negative correlations between cytotoxic T-cell responses and serum 
AMH, oestradiol and progesterone levels were detected (Joonè et al., 2019). Clarifying the 
role of cytotoxic T-cells during pZP immunocontraception warrants further research.  
 
3.2 Recombinant ZP vaccines in mares  
Despite its recognised successful administration for population management in various 
species, important limitations are associated with native pZP vaccine. These include 
restriction of registration as a commercial product due to its biological origin and associated 
risks of disease transfer and the uneconomical and cumbersome production methods 
(Nolan et al., 2019). A vaccine incorporating recombinant ZP proteins has the potential to be 
produced more economically and efficiently, providing a purer and more standardised 
product with the potential for international distribution (Gupta and Bansal, 2010). The use 
in mice of a reZP vaccine derived from an Escherichia coli platform expressing porcine ZP 
glycoproteins 3 and 4 was reported (Gupta et al., 2013). This vaccine was included with 
native pZP vaccine in a comparative study in mares to assess its contraceptive efficacy, 
ovarian, clinical and immunological effects (Joonè et al., 2017a). Freund’s modified 
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complete and FIA adjuvants were incorporated into this reZP vaccine formulation for 
administration in seven mares. The results in these mares suggested that reZP exerted a 
partial, but not statistically significant, contraceptive effect. Furthermore, anti-ZP antibody 
titres measured using enzyme-linked immunosorbent assay (EIA) following reZP treatment 
were lower than the titres induced by native pZP (Joonè et al., 2017a) (Figure 1).  
Subsequently, in collaboration with Biosciences, Council for Scientific and Industrial 
Research, South Africa, the reZP was modified and incorporated in a novel reZP vaccine and 
was observed to induce the development of anti-ZP antibody titres comparable to those in 
native pZP-treated horses (Nolan et al., 2019) (Figure 1). In addition to observing this 
immunological response, notably both the native pZP and the reZP vaccines in this study 
were formulated with non-Freund’s adjuvants and treated mares showed varying levels of 
ovarian suppression (Nolan et al., 2018).  
 
3.3 Zona pellucida-based vaccines formulated with non-Freund’s adjuvants in mares 
Our initial studies observed an unacceptable prevalence of adverse injection site 
reactions in both vaccine-treated (pZP and reZP) and adjuvant-treated control mares. These 
ranged from ultrasonographically visible intramuscular lesions to overt sterile granuloma 
formation (Joonè et al., 2017a). These findings were supported by reports describing similar 
findings in mares (Bechert et al., 2013) and treated elephant cows (Bertschinger et al., 
2018). Freund’s adjuvants were common to these studies. Consequently, an important focus 
in our research group has been investigating suitable alternatives to Freund’s adjuvants. A 
pilot study in geldings compared various alternative adjuvants and established that the 
commercially available adjuvants PetGel A (MontanideTM PetGel A, Seppic, France) and Poly 
(I:C) (HMW VacciGradeTM, Invivogen, USA) were promising alternatives for incorporation in 
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ZP vaccines (Nolan et al., 2019). Subsequently, these two adjuvants replaced Freund’s 
adjuvants for incorporation into vaccine formulations with both native pZP and the novel 
reZP for investigation in a comparative mare study. Neither administration of pZP nor the 
reZP vaccines formulated with PetGel A and Poly (I:C) (nor indeed the adjuvant-treated 
controls) were associated with any appreciable adverse post-injection effects in treated 
mares (Nolan et al., 2018).  
 
3.4. Zona pellucida-based vaccination in African elephants 
The first field trial with pZP vaccine administration in free-ranging African elephants 
occurred from 1996 to 2000 in the Kruger National Park of South Africa (Fayrer-Hosken et 
al., 2000). Animals were immobilised to facilitate ultrasonographical pregnancy detection 
and hand injected with native pZP vaccine and subsequently boosted via remotely delivered 
treatments. An initial contraceptive efficacy of approximately 58% later improved to 80% by 
decreasing the intervals between the three administered treatments to two weeks. Since 
then, the vaccine has proved to be a practical and non-lethal method of manipulating the 
growth rate of elephant populations particularly in small to medium-sized fenced reserves in 
South Africa (Bertschinger et al., 2018). In smaller reserves, enabling individual cow 
identification, a contraceptive efficacy of 100% was achieved whereas in larger reserves, 
where this is impossible, a blanket treatment approach was shown to be ≥90% effective 
(Bertschinger et al., 2018).  By 2018, >800 cows were undergoing treatment across 27 South 
African reserves (Nolan, 2019). 
 
4. Measuring the ovarian response to treatment in mares and elephants 
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The mare studies reviewed here used clinical examination of the ovaries and 
reproductive tracts corroborated by laboratory measurements of ovarian steroids to define 
post-treatment ovarian inactivity. Anoestrus was defined by bilaterally small ovaries (both 
<25 cm3) lacking a corpus luteum or any follicle >15 mm in diameter and basal SPC 
(<1ng/mL) (Botha et al., 2008; Schulman et al., 2013; Joonè et al., 2017a; Nolan et al., 2018; 
Nolan et al., 2019). This enabled relatively precise determination of both the onset of 
ovarian suppression and reversibility over extended post-treatment monitoring periods. 
Interestingly, in the final study reviewed in this series, both anti -pZP and -reZP antibody 
titres were significant predictors of ovarian shutdown (P= 0.001 95% CI [0.644, 2.537], P= 
0.001, 95% CI [1.321, 4.758], respectively (Nolan et al., 2019). This model was used to 
monitor luteal profiles as an indication of post-treatment ovarian response to GnRH vaccine 
in free-ranging elephant cows (Benavides Valades et al., 2012). The study circumvented 
serial serum sampling by non-invasive serial sampling for faecal progestagen metabolite 
(FPM) evaluation via an EIA detecting faecal 5α-reduced pregnanes. 
Anti-Müllerian hormone concentration was measured using a commercially available EIA 
in mares treated with both anti-GnRH and-ZP-based vaccines and was compared with other 
established clinical and laboratory variables including age, ovarian volumes, follicular 
dynamics and SPC (Joonè et al., 2018; Nolan et al., 2018). In these studies, AMH levels in 
GnRH-treated mares were unchanged, whereas pZP-treated mares showed profound and 
reversible AMH suppression (Joonè et al., 2018), supporting AMH as a marker for ovarian 
function during ZP-based immunocontraception. A single sampling intervention for AMH 
analysis, unlike sampling for ovarian steroids or their metabolites would suffice to define 
ovarian and follicular status. This may prove useful in situations where serial gynaecological 
exams are unfeasible, such as in free-ranging African elephant cows. 
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5. Conclusions and future directions 
Fayrer-Hosken (2008) stated “The ultimate goal of fertility control of a population is an 
agent that it is non-toxic, completely reversible, has multi-year efficacy, is easily 
administered, is devoid of behavioural side-affects, cost-effective and is efficacious in 
multiple species and both sexes”. The administration of contraceptive agents and the 
subsequent monitoring of their efficacy and safety profiles in free-ranging domestic and 
wildlife populations is associated with several unique challenges. Previously, most reported 
mare studies described vaccine application in feral or free-roaming horse populations 
(Kirkpatrick et al., 1997; Turner Jr et al., 1997) with obvious limitations in these populations 
on the frequency and scope of sampling interventions for clinical data, hormonal and 
immunological assays. Safety profiles, including injection site reactions, were difficult to 
assess without compliance and continuous access. Further research-associated limitations in 
wildlife species have included lack of controls, identification of individual study animals and 
relatively brief monitoring durations, impeding detection of reversibility (Kirkpatrick et al., 
1990; Turner Jr et al., 1997; Turner Jr et al., 2001; Turner et al., 2002).  
This sequence of reported studies has shown that both GnRH and ZP-based vaccines 
induce reversible suppression of ovarian cyclic activity in mares. Using domestic mares 
facilitated serial, in-depth clinical and laboratory observations of individual animals over 
extended observation periods. Results improved understanding of these vaccines’ 
mechanism of action and validated the use of serum AMH concentrations for the 
monitoring of ovarian activity in horses not amenable to serial gynaecological examinations.  
The development of a synthetic pZP vaccine showed significant progress.hese initial 
studies support its further investigation as a potentially effective alternative to the native 
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pZP vaccine without the associatedlimitations  particulary with its production and supply. 
Moreover, alternatives to Freund’s adjuvants for incorporation into ZP-based vaccine 
formulations have undergone preliminary investigation with promising results that 
supported immunological efficacy with an enhanced safety profile in horses. Future 
investigations should aim at further clarifying the ovarian, immunological and importantly, 
the contraceptive effects of reZP vaccines formulated with non-Freund’s adjuvants. Fulfilling 
these aims supports the important goal of investigating the administration of the novel reZP 
vaccine in free-ranging elephant cows as a population control tool with the abovementioned 
potential benefits.   Furthermore, management circumstances may indicate selection of 
alternatives to ZP-based vaccines in elephant cows, warranting further investigation of 
GnRH vaccines.  
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Figure 1  
Mean anti-pZP antibody response expressed as a proportion of a positive standard (+ s.e.)  
A: pZP and reZP* vaccines formulated with Freund’s modified complete (FMCA) and incomplete (FIA) 
adjuvants for primary and booster vaccinations, respectively 
Control; pZP & FMCA/FIA; reZP & FMCA/FIA at four time points: i (pre-vaccination); ii (28 d post 
primary vaccination); iii (28 d post booster vaccination), iv (70 d post booster vaccination) (Joonè et 
al., 2017a) 
B: pZP and reZP** vaccines formulated with PetGelA and Poly (I:C) adjuvants for primary and 
booster (pZP single booster; reZP double booster) vaccinations 
Control; pZP & PetGel A & Poly (I:C); reZP** & PetGel A & Poly (I:C) at five time points: i (pre-
vaccination (and primary vaccination for reZP)); ii (35 d post primary vaccination for reZP and pre-
vaccination pZP and control); iii (35 d post primary/booster vaccination); iv (35 d post booster/ 
second booster vaccination); v (70 d post booster/second booster vaccination) (Nolan et al., 2019) 
Arrows depict approximate treatment time  
*Gupta et al., 2013; **CSIR Biosciences, South Africa 
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